Engineered therapeutic antibodies with enhanced effector functions: Clinical application of the Potelligent® Technology

Takefumi Matsushita, Ph.D.

Department of Clinical Development, Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan

INTRODUCTION

With more than 30 therapeutic antibodies approved worldwide, therapeutic antibodies have become a major category in the pharmaceutical market. In an effort to further expand the potential of therapeutic antibodies, several approaches are being employed, such as improving the effector functions of the antibodies, designing antibody-drug conjugates, and downsizing the antibody molecule. Among these approaches, enhancing antibody-dependent cellular cytotoxicity (ADCC), which is the major effector function of an antibody, is thought to be one of the most promising and practical approaches to make an antibody more efficacious. In this “Perspective”, we have provided an overview of such ADCC-enhancing technologies, while focusing mainly on our Potelligent® Technology, which has been most extensively tested in clinical trials.

ADCC AS A MAJOR MODE OF ACTION OF ANTIBODY THERAPY

ADCC is a cytolytic effector mechanism by which an antigen-specific antibody stimulates immune effector cells, primarily NK (natural killer) cells, to kill antigen-expressing cells. This process is triggered by the binding of the Fc domain of an antibody to the FcγRs (FcγRIIIa in human) on NK cells, followed by the activation of NK cells, and then, the destruction of target cells. A number of preclinical studies have shown that ADCC is a major mechanism of action of antitumor antibodies such as rituximab, trastuzumab, and alemtuzumab. Furthermore, the importance of ADCC has also been shown by clinical trials, which have provided evidence of a significant correlation between FcγRIIIa functional polymorphisms and clinical outcomes, demonstrated by multiple therapeutic antibodies, including rituximab, trastuzumab, cetuximab, and infliximab. Thus, ADCC is now considered an important clinical mechanism, and enhancing ADCC has become a logical approach to improve the efficacy of therapeutic antibodies.

ADCC-ENHANCING TECHNOLOGIES

ADCC can be enhanced in several different ways, one of which is the modification of amino acids in the Fc domain. Shields et al. have shown that the Fc-domain variants with up to 3 mutations improved binding of the Fc domain with FcγRIIIa and enhanced the capacity for ADCC [1]. More recently, Lazar et al. have utilized computational 3D modeling methods to design an IgG1-Fc variant with 3 mutations that showed markedly enhanced FcγRIII binding, ADCC, and, importantly, B-cell depletion in monkeys by using an anti-CD20 system [2].

The other established approach for enhancing ADCC is the modification of the oligosaccharide structure in the Fc domain. The Fc region of an IgG molecule has 2 N-linked
glycosylation sites located at N297 (asparagine 297) of the 2 heavy chains. The N297-linked oligosaccharide chains are of the complex bi-antennary type, which has structural heterogeneity in certain moieties, and this heterogeneity affects the antibody’s effector functions. While it was known that the presence of the terminal sialic acid might affect FcyRIIIa binding and ADCC, Umaña et al. have shown that increased amount of bisecting GlcNAc (N-acetyl-D-glucosamine) adjacent to the core mannose resulted in a 10-fold ADCC enhancement [3]. Meanwhile, our group, as well as several others, has been focusing on the fucose residue for its possible effect on ADCC; these studies eventually led to the establishment of the Potelligent Technology.

**POTELLIGENT® TECHNOLOGY**

Potelligent® Technology, one of the most potent technologies for enhancing ADCC, originated from the initial discovery that reducing or eliminating fucose from the oligosaccharides on the Fc domain significantly increased FcyRIIIa binding and dramatically enhanced ADCC by >100 fold; the impact of this modification was, by far, greater than that of any other glycomodifications (Fig. 1A) [4]. Intensive studies have shown that a defucosylated antibody has a number of desirable features for clinical applications: it can induce potent ADCC at a lower dose and antigen density than a conventional antibody can [5], and it induces more potent in vivo anti-tumor activity than its conventional counterpart in animal models [5]. Additionally, in contrast to the antibodies obtained by introducing amino acid mutations, an antibody with no fucose is a natural component of human serum, and therefore, has a lower risk of immunogenicity.

For clinical application of this technology, it was critical to establish a robust production system, because all the commonly used host cells for biologics manufacturing produce highly fucosylated proteins. To this end, we generated a genetically engineered Chinese hamster ovary (CHO) host cell line that is incapable of adding fucose to an oligosaccharide chain; this was achieved by knocking out the FUT8 gene, which encodes the only enzyme that catalyzes the core fucosylation in mammals [6]. The established FUT8−/− CHO cells were confirmed to produce fully defucosylated antibodies (Fig. 1B), with their other basic characteristics being undistinguishable from a wild-type CHO cell, thereby making the knockout cell an ideal host for ADCC-enhanced antibodies.

**CLINICAL APPLICATION OF THE POTELLIGENT® TECHNOLOGY**

To date, as many as 10 Potelligent®-applied antibodies produced by using the FUT8−/− CHO cells have been investigated in human clinical trials, and a growing body of evidence has now confirmed the clinical benefits of this technology. Among those antibodies, the anti-CCR4 antibody, KW-0761 (mogamulizumab), is the most advanced. In a phase I/II study in patients with relapsed/refractory cutaneous T-cell lymphoma, KW-0761 produced an overall response rate of 39% with a manageable safety profile [7]. In a separate pivotal phase II study in patients with relapsed adult T-cell leukemia-lymphoma, a remarkable overall response rate of 50% was observed [8]; a new drug application for this antibody was filed with the Japanese regulatory agency in April 2011.

**CONCLUSION**

With therapeutic antibodies becoming a major pharmaceutical entity, an effort to create next-generation antibodies...
is in full swing. The Potelligent® defucosylation technology is among the approaches for creating such engineered antibodies, and it has proven clinically effective. More clinical data from multiple antibodies are needed to fully evaluate the clinical benefits of this technology.

REFERENCES

1. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276:6591-604.
2. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006;103:4005-10.
3. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 1999;17:176-80.
4. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylgalactosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
5. Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004;64:2127-33.
6. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004;87:614-22.
7. Duvic M, Pinter-Brown L, Foss FM, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood 2010;116:abst 962.
8. Ishida T, Joh T, Uike N, et al. Multicenter phase II study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL). Blood 2010;116:abst 285.